What if we could detect a lung cancer patient’s relapse months before it’s visible on scans? A recent study in Nature Magazine sheds light on the powerful potential of molecular residual disease (MRD) analysis. #lungcancer
Plasma-based molecular residual disease analysis shows the potential to predict disease recurrence in lung cancer patients by 4.7 months.
